別品名 |
Buphenyl, Sodium 4-phenylbutyrate, Tributyrate, Benzenebutanoic acid, sodium salt
|
別包装 |
あり
|
純度 |
>=98%
|
分子量 |
186.18
|
CAS RN® |
1716-12-7
|
化合物の概要 |
HDAC inhibitor.
|
構造 |
C10H11O2Na
|
溶媒 |
Soluble in water, ethanol, DMSO.
|
使用目的 |
Phenylbutyrate is an inhibitor of histone deacetylase (HDAC) that exhibits neuroprotective and anticancer chemotherapeutic activities. In cellular and animal models of pancreatic cancer, phenylbutyrate inhibits cellular proliferation and tumor growth. This compound is clinically used to treat urea cycle disorders, as it allows excretion of excess nitrogen waste. In animal models of Alzheimer’s disease, phenylbutyrate prevents neuronal loss and normalizes brain pathology.
|
その他 |
[融点]214℃-220℃ [外観]White crystalline powder
|
参考文献 |
Cuadrado-Tejedor M, Ricobaraza AL, Torrijo R, et al. Phenylbutyrate is a multifaceted drug that exerts neuroprotective effects and reverses the Alzheimer's disease-like phenotype of a commonly used mouse model. Curr Pharm Des. 2013;19(28):5076-84. PMID: 23448463.Dovzhanskiy DI, Hartwig W, Lazar NG, et al. Growth inhibition of pancreatic cancer by experimental treatment with 4-phenylbutyrate is associated with increased expression of Connexin 43. Oncol Res. 2012;20(2-3):103-11. PMID: 23193916.Iannitti T, Palmieri B. Clinical and experimental applications of sodium phenylbutyrate. Drugs R D. 2011 Sep 1;11(3):227-49. PMID: 21902286.Batshaw ML, MacArthur RB, Tuchman M. Alternative pathway therapy for urea cycle disorders: twenty years later. J Pediatr. 2001 Jan;138(1 Suppl):S46-54; Erratum in: J Pediatr 2002 Apr;140(4):490. PMID: 11148549.
|
※サムネイル画像をクリックすると拡大画像が表示されます。
|
|
|
メーカー |
品番 |
包装 |
LKT
|
P2815
|
25 G
|
※表示価格について
当社在庫 |
なし
|
納期目安 |
1週間程度
|
保存温度 |
常温
|
|